NovoThirteen® (rFXIII) (NN1841)

:FXIII Congenital deficiency
:Filed for registration

A recombinant coagulation factor XIII. Launched in the EU and Canada and approved in Switzerland. Submitted for marketing authorisation in the US and other larger markets.

Company announcements
Novo Nordisk provides update on corporate strategy at its Capital Markets Day (26 Sep 2008)
Novo Nordisk's Capital Markets Day 2004 (05 Oct 2004)
Read more company announcements

Press releases
Novo Nordisk receives positive opinion on recombinant factor XIII from the European regulatory authorities (25 May 2012)
Novo Nordisk presents positive clinical data on two investigational compounds within bleeding disorders (07 Dec 2010)
Novo Nordisk begins phase 1 study with rFXIII in cardiac surgery (18 Oct 2005)
Read more press releases

Scientific abstracts
Blood (2012)
Read more scientific abstracts

You can search for more clinical trials on http://clinicaltrials.gov
  •